Twist Bioscience Corp (0ME.BE)
| Previous close | 43.46 |
| Open | 42.81 |
| Bid | 42.95 x 0 |
| Ask | 43.57 x 0 |
| Day's range | 42.38 - 43.26 |
| 52-week range | 11.69 - 46.22 |
| Volume | |
| Avg. volume | 5 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications
SOUTH SAN FRANCISCO, Calif., May 13, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA (dsDNA) up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications.
- Business Wire
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 08, 2024--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) ("Twist" or the "Company"), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 87,200 restricted stock units ("RSUs") to 26 recently hired individuals as an inducement material to their acceptance of employment with Twist. The employment inducem
- Business Wire
Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., May 02, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.
